Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MASP2 | O00187 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9667465 | 0.85 | USP2 (0.30) | ALDH1A1USP2TP53ADORA3HPGD | |
| SCHEMBL2790086 | 0.64 | TDP1 (0.31) | — | |
| SCHEMBL6322394 | 0.63 | DCPS (0.30) | — | |
| SCHEMBL6323165 | 0.60 | DPP4 (0.32) | — | |
| SCHEMBL1627470 | 0.60 | PI4KA (0.31) | XDH | |
| SCHEMBL30379561 | 0.56 | NUDT1 (0.46) | ALDH1A1MEN1NUDT1KMT2AUSP2 | |
| SCHEMBL29061394 | 0.56 | ALDH1A1 (0.38) | ALDH1A1KMT2AUSP2TP53ADORA3 | |
| SCHEMBL27053802 | 0.56 | NPSR1 (0.35) | ALDH1A1USP2TP53ADORA3HPGD | |
| Thioguanine SCHEMBL3701 | 0.54 | PNP (0.62) | ALDH1A1MEN1KMT2AUSP2TP53 | |
| SCHEMBL9667463 | 0.54 | CYP3A4 (0.31) | ALDH1A1USP2TP53ADORA3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049125-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | Landau, Bernard R. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2007098183-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | LANDAU BERNARD R (US) | 2007-08-30 | — | — | WO | claimed |
| EP-3990494-A1 | IL1RAP BINDING PROTEINS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-05-04 | — | — | EP | disclosed |
| EP-3917963-A1 | BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB FOR TREATING CANCER | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| EP-3917964-A1 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021018941-A1 | METHODS OF TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020261097-A1 | IL1RAP BINDING PROTEINS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020160375-A9 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020160365-A1 | BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB FOR TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160375-A1 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020030570-A1 | COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2005086951-A2 | HYPOXIA-ACTIVATED ANTI-CANCER AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005079192-A2 | NOVEL TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005034873-A2 | A METHOD FOR REDUCING ANTI-NEOPLASTIC AGENT INDUCED SIDE-EFFECTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2004087075-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004062604-A2 | TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004037200-A2 | RETICULOCYTE DEPLETION SIGNATURES | ICONIX PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003082301-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003072043-A2 | A METHOD OF RECUDING ANTI-NEOPLASTIC AGENT INDUCED SIDE EFFECTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |